Skip to main content
SpringerLink
Log in

Being Led Down the Wrong Garden PATH: the Importance of Knowledge and Facts for the Crossroads

  • Correspondence
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Gafni A, Birch S. Building bridges between academic research and policy formulation: the PRUFE framework [letter]. Pharmacoeconomics 2007; 25 (6): 523–528

    Article  PubMed  Google Scholar 

  2. Goeree R, Levin L. Building bridges between academic research and policy formulation: the PRUFE framework. An integral part of Ontario’s evidence-based HTPA process. Pharmacoeconomics 2006; 24 (11): 1143–1156

    Article  PubMed  Google Scholar 

  3. Birch S, Gafni A. The biggest bang for the buck or bigger bucks for the bang: the fallacy of the cost-effectiveness threshold. J Health Serv Res Policy 2006 Jan; 11 (1): 46–51

    Article  PubMed  Google Scholar 

  4. Gafni A, Birch S. Inclusion of drugs in provincial drug benefit programs: should’ reasonable decisions’ lead to uncontrolled growth in expenditures? CMAJ 2003 Apr 1; 168 (7): 849–851

    PubMed  Google Scholar 

  5. Gafni A, Birch S. NICE methodological guidelines and decision making in the National Health Service in England and Wales. Pharmacoeconomics 2003; 21 (3): 149–157

    Article  PubMed  Google Scholar 

  6. Birch S, Gafni A. Cost effectiveness/utility analyses: do current decision rules lead us to where we want to be? J Health Econ 1992 Oct; 11 (3): 279–296

    Article  PubMed  CAS  Google Scholar 

  7. Gafni A, Birch S. Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. CMAJ 1993 Mar 15; 148 (6): 913–917

    PubMed  CAS  Google Scholar 

  8. Birch S, Gafni A. The’ NICE’ approach to technology assessment: an economics perspective. Health Care Manag Sci 2004 Feb; 7 (1): 35–41

    Article  PubMed  Google Scholar 

  9. Birch S, Gafni A. Information created to evade reality (ICER): things we should not look to for answers. Pharmacoeconomics 2006; 24 (11): 1121–1131

    Article  PubMed  Google Scholar 

  10. The Ontario Health Technology Advisory Committee (OHTAC). Ministry of Health and Long-Term Care, 2007 [online]. Available from URL: http://www.health.gov.on.ca/ english/providers/prog ram/mas/ohtac_about.html [Accessed 2007 Mar 30]

  11. Program for Assessment of Technology in Health (PATH) [online]. Available from URL: http://www.path-hta.ca [Accessed 2007 Mar 30]

  12. Ministry of Health and Long-Term Care [online]. Available from URL: http://www.health.gov.on.ca/ [Accessed 2007 Mar 30]

  13. Alter DA, Stukel TA, Newman A. Proliferation of cardiac technology in Canada: a challenge to the sustainability of Medicare. Circulation 2006 Jan 24; 113 (3): 380–387

    Article  PubMed  Google Scholar 

  14. Ayanian JZ. Rising rates of cardiac procedures in the United States and Canada: too much of a good thing? Circulation 2006 Jan 24; 113 (3): 333–335

    Article  PubMed  Google Scholar 

  15. Halpern MT, Lacey M, Clark MA, et al. Changing treatment patterns for coronary artery revascularization in Canada: the projected impact of drug eluting stents [letter]. BMC Cardiovasc Disord 2004; 4: 23

    Article  PubMed  Google Scholar 

  16. Lucas FL, DeLorenzo MA, Siewers AE, et al. Temporal trends in the utilization of diagnostic testing and treatments for cardiovascular disease in the United States, 1993–2001. Circulation 2006 Jan 24; 113 (3): 374–379

    Article  PubMed  CAS  Google Scholar 

  17. Maier W, Abay M, Cook S, et al. The 2002 European registry of cardiac catheter interventions. Int J Cardiol 2006 Nov 18; 113 (3): 299–304

    Article  PubMed  Google Scholar 

  18. Cardiac Care Network of Ontario (CCN). Working group on drug eluting stents. Report on initial utilization strategy: final report and recommendations. CCN 2002 December 2 [online]. Available from URL: http://www.ccn.on.ca/pdfs/FinalDrug ElutingMaster2_Dec2002.pdf [Accessed 2007 Mar 30]

    Google Scholar 

  19. Packer C, Simpson S, Stevens A. International diffusion of new health technologies: a ten-country analysis of six health technologies. Int J Technol Assess Health Care 2006; 22 (4): 419–428

    Article  PubMed  Google Scholar 

  20. Grilli R, Taroni F. Managing the introduction of expensive medical procedures: use of a registry. J Health Serv Res Policy 2006 Apr; 11 (2): 89–93

    Article  PubMed  Google Scholar 

  21. Yan BP, Ajani AE, Duffy SJ, et al. Use of drug-eluting stents in Victorian public hospitals. Med J Aust 2006 Oct 2; 185 (7): 363–367

    PubMed  Google Scholar 

  22. Wright C. The rise and rise of stents. Scrip 2006 Jan: 10–13 [online]. Available from URL: http://www.scripmag.com [Accessed 2007 Mar 30]

    Google Scholar 

  23. Thanigaraj S, Wollmuth JR, Zajarias A, et al. From randomized trials to routine clinical practice: an evidence-based approach for the use of drug-eluting stents. Coron Artery Dis 2006 Dec; 17 (8): 673–679

    Article  PubMed  Google Scholar 

  24. Huang HW, Brent BN, Shaw RE. Trends in percutaneous versus surgical revascularization of unprotected left main coronary stenosis in the drug-eluting stent era: a report from the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). Catheter Cardiovasc Interv 2006 Dec; 68 (6): 867–872

    Article  PubMed  Google Scholar 

  25. Lev EI, Tayyan N, Raizner AE, et al. Initial impact of drug-eluting stent use on the spectrum of patients undergoing percutaneous coronary intervention. Coron Artery Dis 2006 May; 17 (4): 379–384

    Article  PubMed  Google Scholar 

  26. Canadian Agency for Drugs and Technologies in Health (CADTH). 2006 CADTH Invitational Symposium [online]. Available from URL: http://www.cadth.ca/index.php/en/eve nts/symposium-2006 [Accessed 2007 Mar 30]

  27. Ontario Ministry of Health and Long-Term Care. Health Technology: OHTAC recommendations [online]. Available from URL: http://www.health.gov.on.ca/english/providers/program /mas/tech/recommend/rec_mn.html [Accessed 2007 Mar 30]

  28. Ontario Ministry of Health and Long Term Care. OHTAC recommendation: drug eluting stents (DES) [online]. Available from URL: http://www.health.gov.on.ca/english/providers/ program/mas/tech/recommend/rec_des_102105.pdf [Accessed 2007 Mar 30]

  29. Washington State Health Care Authority Health Technology Assessment Program [online]. Available from URL: http:// www.hta.hca.wa.gov/assessment/index.shtml [Accessed 2007 Apr 5]

  30. McIsaac ML, Goeree R, Brophy JM. Primary data collection in health technology assessment. Int J Technol Assess Health Care 2007; 23 (1): 2–9

    Article  Google Scholar 

Download references

Acknowledgements

The authors have no conflicts of interest to declare.

Author information

Authors and Affiliations

  1. Program for Assessment of Technology in Health (PATH), St. Joseph’s, McMaster University, Hamilton, Ontario, Canada

    Ron Goeree, Daria O’Reilly, Jean-Eric Tarride, Jim Bowen, Gord Blackhouse, Kaitryn Campbell, Rob Hopkins, Morgan Lim & Lisa Patterson

  2. Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada

    Ron Goeree, Daria O’Reilly, Jean-Eric Tarride, Jim Bowen, Gord Blackhouse, Kaitryn Campbell, Rob Hopkins, Morgan Lim & Lisa Patterson

Authors
  1. Ron Goeree
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daria O’Reilly
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jean-Eric Tarride
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jim Bowen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gord Blackhouse
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kaitryn Campbell
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rob Hopkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Morgan Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Lisa Patterson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goeree, R., O’Reilly, D., Tarride, JE. et al. Being Led Down the Wrong Garden PATH: the Importance of Knowledge and Facts for the Crossroads. Pharmacoeconomics 25, 528–532 (2007). https://doi.org/10.2165/00019053-200725060-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200725060-00008

Keywords

Search

Navigation